Atezolizumab

NeoTRIP: EFS in neoadjuvant atezolizumab with taxane/carboplatin ± anthracycline in high-risk TNBC 1:07
NeoTRIP: EFS in neoadjuvant atezolizumab with taxane/carboplatin ± anthracycline in high-risk TNBC
Kevin Kalinsky • 22 Oct 2023
Unexpected safety data in TREASURE: thoracic radiotherapy with atezolizumab in SCLC 2:36
Unexpected safety data in TREASURE: thoracic radiotherapy with atezolizumab in SCLC
Andrea Ardizzoni • 23 Oct 2023
Utilizing novel biomarkers as treatment personalization tools in colorectal cancer 2:01
Utilizing novel biomarkers as treatment personalization tools in colorectal cancer
Filippo Pietrantonio • 22 Oct 2023
DARWIN II: deciphering anti-tumor response & resistance to IO w/ intratumour heterogeneity in NSCLC 5:11
DARWIN II: deciphering anti-tumor response & resistance to IO w/ intratumour heterogeneity in NSCLC
Crispin Hiley • 22 Oct 2023
Future directions of targeted agents in the treatment of thyroid and neuroendocrine tumors 3:19
Future directions of targeted agents in the treatment of thyroid and neuroendocrine tumors
Enrique Grande • 22 Oct 2023
Key takeaways from the renal and prostate cancer sessions at ESMO 2023 1:08
Key takeaways from the renal and prostate cancer sessions at ESMO 2023
Joaquim Bellmunt • 22 Oct 2023
Sequencing treatment options for HCC 1:06
Sequencing treatment options for HCC
Lorenza Rimassa • 29 Jun 2023
Assessing treatment options for hepatocellular carcinoma 1:16
Assessing treatment options for hepatocellular carcinoma
Lorenza Rimassa • 29 Jun 2023
The role of systemic treatment in early-stage hepatocellular carcinoma 2:32
The role of systemic treatment in early-stage hepatocellular carcinoma
Ghassan Abou-Alfa • 22 Jun 2023
What role does TIGIT inhibition have in treating hepatocellular carcinoma? 3:52
What role does TIGIT inhibition have in treating hepatocellular carcinoma?
Ghassan Abou-Alfa • 22 Jun 2023
The benefits of immunotherapy versus chemotherapy: analyzing the results of the IPSOS trial 2:42
The benefits of immunotherapy versus chemotherapy: analyzing the results of the IPSOS trial
Riyaz Shah • 28 Apr 2023
CheckMate-722: Investigating the addition of immunotherapy to chemotherapy in EGFR-Mutant NSCLC 2:01
CheckMate-722: Investigating the addition of immunotherapy to chemotherapy in EGFR-Mutant NSCLC
Tony Mok • 28 Apr 2023
STELLAR-303: XL092 with atezolizumab compared to regorafenib in patients with mCRC 2:14
STELLAR-303: XL092 with atezolizumab compared to regorafenib in patients with mCRC
J. Randolph Hecht • 2 Jun 2023
CONTACT-303: primary PFS analysis of atezolizumab and cabozantinib in ccRCC 4:15
CONTACT-303: primary PFS analysis of atezolizumab and cabozantinib in ccRCC
Toni Choueiri • 22 May 2023
The future of arginine deprivation therapy in lung cancer 1:36
The future of arginine deprivation therapy in lung cancer
Peter Szlosarek • 18 Apr 2023
Will atezolizumab and bevacizumab be the new SOC in high-risk HCC? 0:31
Will atezolizumab and bevacizumab be the new SOC in high-risk HCC?
Pierce Chow • 18 Apr 2023
The content of VJOncology is intended for healthcare professionals